The current situation of cancer morbidity and mortality in the light of the National Cancer Registry, Hungary. Genes Chromosomes Cancer ; — Current state of ERG as biomarker in prostatic adenocarcinoma.
Curr Cancer Drug Targets ; — The molecular taxonomy of primary prostate cancer.
Что. - спросил Орел. Николь вынужденно улыбнулась.
Cell ; — The mutational landscape of prostate cancer. Eur Urol.
- Я объяснила ему причины.
- Histology of prostate cancer
- A prosztata fájdalomtól
- Теперь я увеличиваю геометрический объем, чтобы он включал примерно тысячу звезд.
- Все дружно решили, что пришельцы задержатся на острове до завтра или послезавтра.
- A prosztatitis telepítése
Nat Genet. SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia ; 14— Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.
Eur J Cancer ; — Integrative clinical genomics of advanced prostate cancer. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer.
Ты всегда была самой смышленой среди детей. Ты заслуживаешь счастья.
The mutational landscape of lethal castration-resistant prostate cancer. Nature ; — Androgen receptor-mediated processes in castrate-resistant metastatic prostate cancer.
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. Increased survival with enzalutamide in prostate volume prostata 40 cc after chemotherapy. Abiraterone in metastatic prostate cancer without previous chemotherapy.
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer PREVAIL : results from a randomised, phase 3 trial.
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Genetic alterations in the PI3K pathway in prostate cancer.
Anticancer Res. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer ; — Combination AZD with enzalutamide significantly delays enzalutamide-resistant prostate cancer in preclinical models.
Mol Cancer Ther. Abi alone in patients with metastatic castration-resistant prostate cancer mCRPC after docetaxel chemotherapy A. J Clin Oncol.
Must understand and voluntarily sign a written informed consent prior to any study-related procedures being performed. Must be able to communicate with the investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules. Healthy male or female of any race between 18 to 50 years of age inclusive at the time of signing the informed consent, and in good health as determined by a physical examination at screening.
Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
Clin Cancer Res. Spatial genomic heterogeneity within localized, multifocal prostate cancer. The importance of DNA methylation in prostate cancer development. J Steroid Biochem Mol Biol.